Demineralization removes residual alendronate in allograft bone procured from donors with a history of bisphosphonate use

Journal of Periodontology

Volumn 82, Issue 2, 2011, Pages 281-286

  Hunter, Shawn A ^a   Orheim, Robert ^b   Sazon, Mia ^b   Newman, Helen ^c   Woll, Judith E ^d   Bergevini, Michael ^e  

^a Immunohematology Reference Laboratory   (United States)

^b Analytical Chemistry   (United States)

^c Veterinary Transplant Services   (United States)

^d Woll Consulting   (United States)

^e LifeNet Health   (United States)

Author keywords

Alendronate; Bone demineralization technique; Bone matrix; Diphosphonates; Homologous; Osteonecrosis; Transplantation

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BONE MATRIX; BONE NECROSIS; BONE TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; COMPARATIVE STUDY; DONOR; FEMALE; HISTOLOGY; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; TRANSPLANTATION;

AGED; ALENDRONATE; BONE DEMINERALIZATION TECHNIQUE; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; BONE TRANSPLANTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEONECROSIS; TISSUE DONORS;

EID: 79951821207     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2010.100236     Document Type: Article

References (29)

1. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 2006;137:1144-1150.
2. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-761. (Pubitemid 46780635)
3. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-1935. (Pubitemid 19148862)
4. Vitté C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast- mediated resorption. Endocrinology 1996;137: 2324-2333.
5. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int 1993;3(Suppl. 3):S13-S16.
6. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: An overview. Int J Clin Pract Suppl 1999; 101:18-26. (Pubitemid 29216601)
7. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-1668. (Pubitemid 41810027)
8. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32:1123-1128. (Pubitemid 41499467)
9. Pearson K, Dock N, Brubaker S, eds. Standards for Tissue Banking. 12th ed. McLean, VA: American Association of Tissue Banks, 2008.
10. Astrand J, Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J Orthop Res 2004;22:244-249. (Pubitemid 38155278)
11. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol 2000;71:1236-1240. (Pubitemid 30655955)
12. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model. J Periodontol 2000;71:1607-1612.
13. Endele R, Loew H, Bauss F. Analytical methods for the quantification of ibandronate in body fluids and bone. J Pharm Biomed Anal 2005;39:246-256. (Pubitemid 41112143)
14. Sakiyama N, Kataoka H, Makita M. Selective and sensitive determination of pamidronate in human plasma and urine by gas chromatography with flame photometric detection. Biomed Chromatogr 1995;9: 243-245.
15. Aspenberg P, Astrand J. Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop Scand 2002;73:20-23. (Pubitemid 34218817)
16. Jakobsen T, Baas J, Bechtold JE, Elmengaard B, Soøballe K. Soaking morselized allograft in bisphosphonate can impair implant fixation. Clin Orthop Relat Res 2007;463:195-201. (Pubitemid 47585271)
17. Jakobsen T, Kold S, Bechtold JE, Elmengaard B, Soøballe K. Local alendronate increases fixation of implants inserted with bone compaction: 12-week canine study. J Orthop Res 2007;25:432-441. (Pubitemid 46542029)
18. Thomopoulos S, Matsuzaki H, Zaegel M, Gelberman RH, Silva MJ. Alendronate prevents bone loss and improves tendon-to-bone repair strength in a canine model. J Orthop Res 2007;25:473-479. (Pubitemid 46542034)
19. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): Initial discovery and subsequent development. J Oral Maxillofac Surg 2009;67(Suppl. 5): 13-18.
20. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117. (Pubitemid 37064711)
21. Allen MR, Burr DB. The pathogenesis of bisphosphonate- related osteonecrosis of the jaw: So many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67(Suppl. 5):61-70.
22. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534. (Pubitemid 38542516)
23. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A four-case report. J Oral Pathol Med 2005;34:613-617. (Pubitemid 41512948)
24. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-1024. (Pubitemid 47240676)
25. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: A retrospective study. Endocr Pract 2007;13:232-238.
26. King AE, Umland EM. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008;28:667-677. (Pubitemid 351620033)
27. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-1491. (Pubitemid 351229318)
28. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA; American Dental Association Council on Scientific Affairs Expert Panel on Bisphosphonate-Associated Osteonecrosis of the Jaw. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139:1674-1677.
29. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: An institutional inquiry. J Am Dent Assoc 2009;140:61-66.